Compare Citius Pharmaceuticals Inc (CTXR) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Williams-Sonoma, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Williams-Sonoma, Inc. trades at $242.1 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is far larger — about 2066.8× Citius Pharmaceuticals Inc's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Williams-Sonoma, Inc. for 59 Days on average.
| CTXR | WSM | |
|---|---|---|
Market Cap | $13.62M | $28.15B |
Volume | 132,438 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $251.81 |
52-Week Low | $0.48 | $168.64 |
Typical Hold Time | 17 Days | 59 Days |
Enterprise Value | $3.79M | $28.65B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Williams-Sonoma (WSM) trades at $241.75, up 0.54% on the day, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.10 surpassing the $2.08 expectation. Revenue for 2025 was $7.71 billion, with a robust net income margin of 14.73% and high ROE of 54.96%. Recent news highlights market share gains and profitability improvements, including a new Pottery Barn collaboration and store expansion.
The outlook for WSM is positive, driven by earnings momentum, margin strength, and strategic initiatives. However, risks include competitive pressures in home furnishings and sensitivity to housing market trends. Analyst consensus is a buy with a $246.31 price target, suggesting modest upside from current levels, supported by institutional confidence and dividend declarations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
